Good morning and welcome everyone to the Liquidia Corporation full year 2024 financial result and corporate update conference call. My name is Shannon, and I will be your conference operator today.

We know that continuous infusion has shown the best efficacy with ... should we expect any differences in the label for YUTREPIA versus TYVASO DPI? I know in the past you've mentioned ...

Liquidia Technologies Inc. (LQDA), with a market capitalization of $1.25 billion, reported its financial results for Q4 2024, revealing a larger-than-expected net loss and a revenue shortfall ...

Liquidia Technologies Inc. (LQDA), with a market capitalization of $1.25 billion, reported its financial results for Q4 2024, revealing a larger-than-expected net loss and a revenue shortfall compared ...

Additionally, with the growing demand for chronic disease treatments and the ageing baby boomer population, the infusion market is set for significant growth. According to the market research ...

The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat ...

Corsair Pharma is planning a Phase 1 clinical trial of its treprostinil skin patch as a treatment for pulmonary arterial hypertension (PAH).

After hours: March 21 at 7:15:55 PM EDT Loading Chart for MNKD ...

As of 2:08:40 pm GMT-4. Market open. Loading Chart for MNKD ...